MMI Secures $125M Series D to Expand Robotic Microsurgery System
MMI has closed a $125 million Series D round to grow its Symani Surgical System globally and build clinical evidence for robotic microsurgery.
Medical Microinstruments (MMI) has raised $125 million in a Series D funding round to accelerate the commercial rollout of its Symani Surgical System, a robotic platform designed for microsurgery procedures, the company announced.
The capital infusion is intended to support geographic market expansion, broaden patient access to the technology, and fund clinical studies that could establish a stronger evidence base for robotic microsurgery as a standard of care across relevant specialties.
Read more Swvl H1 2026 Revenue Jumps 59% to $16.2M on GCC Surge →
The Symani system represents a niche but growing segment of surgical robotics, one focused on the highly precise, small-scale tissue work required in procedures such as reconstructive and lymphatic surgery. Securing a dedicated Series D of this size signals continued investor appetite for specialized robotic surgical platforms beyond the dominant general-surgery systems already on the market.
MMI's financing round underscores a broader industry trend in which medtech companies are competing to prove clinical and economic value for robotic tools in subspecialty surgery, where manual technique limitations create openings for technology-assisted precision. Expanding the clinical evidence base is widely seen as a prerequisite for broader hospital adoption and reimbursement coverage.
Continue reading at GlobeNewswire - Mergers And Acquisitions.
